Literature DB >> 24292107

Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening.

E M Clark1, L Carter, V C Gould, L Morrison, J H Tobias.   

Abstract

SUMMARY: We identified that use of VFA may be cost-effective in either selected women from primary care or women attending after a low trauma fracture.
INTRODUCTION: Lateral DXA scanning of the spine for vertebral fracture assessment (VFA) is used for research, but its wider role is unclear. We aimed to establish whether VFA is cost-effective in women based on two different scenarios: following a low-trauma fracture, and after screening of high-risk women identified in primary care.
METHODS: The fracture cohort (FC) consisted of 377 women and the primary care cohort (PCC) of 251. Vertebral fractures were identified on VFA images by quantitative morphometry (QM). Outcome was cost-effectiveness of VFA, based on predicted change in clinical management defined as the identification of a vertebral fracture in a patient who otherwise falls below the threshold for treatment. FRAX treatment thresholds assessed were (1) 20/3 % thresholds and (2) National Osteoporosis Guidelines Group (NOGG) thresholds.
RESULTS: As a result, 9.8 % from FC and 13.9 % from PCC were identified with vertebral fractures. Management was changed in 21 to 22/377 (5.6-5.8 %) in FC and 12 to 26/251 (4.8-10.4 %) from PCC depending on which thresholds were used. Sensitivity analyses identified medication adherence as the assumption which most influenced the model. The best-estimate cost-per-QALY for use of VFA in FC was £3,243 for 20/3 threshold and £2,130 for NOGG; for PCC, this was £7,831 for 20/3 and was cost-saving for NOGG. Further analyses to adjust for potential false-positive vertebral fracture identification with QM showed VFA was no longer cost-effective.
CONCLUSION: VFA appears to be cost-effective in routine clinical practise, particularly when relatively inaccurate methods of identification of vertebral fractures are used such as QM.

Entities:  

Mesh:

Year:  2013        PMID: 24292107     DOI: 10.1007/s00198-013-2567-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  38 in total

Review 1.  The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Authors:  Mickaël Hiligsmann; Annelies Boonen; Véronique Rabenda; Jean-Yves Reginster
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2012-04       Impact factor: 2.217

Review 2.  FRAX and its applications to clinical practice.

Authors:  John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey
Journal:  Bone       Date:  2009-02-03       Impact factor: 4.398

3.  A revised clinician's guide to the prevention and treatment of osteoporosis.

Authors:  Bess Dawson-Hughes
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

4.  Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting.

Authors:  T Fuerst; C Wu; H K Genant; G von Ingersleben; Y Chen; C Johnston; M J Econs; N Binkley; T J Vokes; G Crans; B H Mitlak
Journal:  Osteoporos Int       Date:  2008-12-13       Impact factor: 4.507

5.  Effect of a case-finding strategy for osteoporosis on bisphosphonate prescribing in primary care.

Authors:  L S Morrison; J H Tobias
Journal:  Osteoporos Int       Date:  2004-06-02       Impact factor: 4.507

6.  Algorithm-based qualitative and semiquantitative identification of prevalent vertebral fracture: agreement between different readers, imaging modalities, and diagnostic approaches.

Authors:  Lynne Ferrar; Guirong Jiang; John T Schousboe; Charles R DeBold; Richard Eastell
Journal:  J Bone Miner Res       Date:  2008-03       Impact factor: 6.741

7.  Routine versus targeted vertebral fracture assessment for the detection of vertebral fractures.

Authors:  E T Middleton; S A Steel
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

8.  Fracture outcomes related to persistence and compliance with oral bisphosphonates.

Authors:  Arlene M Gallagher; Stephan Rietbrock; Melvin Olson; Tjeerd P van Staa
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

Review 9.  Vertebral Fracture Assessment by dual-energy X-ray absorptiometry: insurance coverage issues in the United States. A White Paper of the International Society for Clinical Densitometry.

Authors:  Andrew J Laster; E Michael Lewiecki
Journal:  J Clin Densitom       Date:  2007-06-28       Impact factor: 2.617

10.  Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: Cohort for Skeletal Health in Bristol and Avon (COSHIBA).

Authors:  Emma M Clark; Virginia Gould; Leigh Morrison; A E Ades; Paul Dieppe; Jon H Tobias
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

View more
  8 in total

Review 1.  Spinal radiographs in those with back pain-when are they appropriate to diagnose vertebral fractures?

Authors:  E M Clark; S R Cummings; J T Schousboe
Journal:  Osteoporos Int       Date:  2017-04-25       Impact factor: 4.507

2.  Impact of mild and moderate/severe vertebral fractures on physical activity: a prospective study of older women in the UK.

Authors:  U A Al-Sari; J H Tobias; E M Clark
Journal:  Osteoporos Int       Date:  2018-09-07       Impact factor: 4.507

Review 3.  Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis.

Authors:  Gherardo Mazziotti; Andrea G Lania; Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2022-03-14       Impact factor: 43.330

4.  Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.

Authors:  Gherardo Mazziotti; Rebecca Pedersini; Walter Vena; Deborah Cosentini; Flaminia Carrone; Stella Pigni; Edda L Simoncini; Rosalba Torrisi; Alberto Zambelli; Davide Farina; Luca Balzarini; Andrea G Lania; Alfredo Berruti
Journal:  Calcif Tissue Int       Date:  2022-07-28       Impact factor: 4.000

Review 5.  Skeletal health in patients with differentiated thyroid carcinoma.

Authors:  M Cellini; M Rotondi; M L Tanda; E Piantanida; L Chiovato; P Beck-Peccoz; Andrea Lania; G Mazziotti
Journal:  J Endocrinol Invest       Date:  2020-07-21       Impact factor: 4.256

Review 6.  Update on vertebral fractures in pituitary diseases: from research to clinical practice.

Authors:  Flaminia Carrone; Salvatore Ariano; Sara Piccini; Davide Milani; Marco Mirani; Luca Balzarini; Andrea Gerardo Lania; Gherardo Mazziotti
Journal:  Hormones (Athens)       Date:  2021-02-19       Impact factor: 2.885

7.  Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice.

Authors:  Gherardo Mazziotti; Walter Vena; Rebecca Pedersini; Sara Piccini; Emanuela Morenghi; Deborah Cosentini; Paolo Zucali; Rosalba Torrisi; Silvio Sporeni; Edda L Simoncini; Roberto Maroldi; Luca Balzarini; Andrea G Lania; Alfredo Berruti
Journal:  J Bone Oncol       Date:  2022-03-09       Impact factor: 4.072

Review 8.  Current Applications and Selected Technical Details of Dual-Energy X-Ray Absorptiometry.

Authors:  Piotr Sawicki; Marek Tałałaj; Katarzyna Życińska; Wojciech S Zgliczyński; Waldemar Wierzba
Journal:  Med Sci Monit       Date:  2021-06-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.